These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 30944164)

  • 21. Oral and Gut Microbial Diversity and Immune Regulation in Patients with HIV on Antiretroviral Therapy.
    Annavajhala MK; Khan SD; Sullivan SB; Shah J; Pass L; Kister K; Kunen H; Chiang V; Monnot GC; Ricupero CL; Mazur RA; Gordon P; de Jong A; Wadhwa S; Yin MT; Demmer RT; Uhlemann AC
    mSphere; 2020 Feb; 5(1):. PubMed ID: 32024712
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Survival, clinical and biological outcomes of HIV-infected children treated by antiretroviral therapy in Africa: systematic review, 2004-2009].
    Ndondoki C; Dabis F; Namale L; Becquet R; Ekouevi D; Bosse-Amani C; Arrivé E; Leroy V
    Presse Med; 2011; 40(7-8):e338-57. PubMed ID: 21295437
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cotrimoxazole prophylaxis by HIV-infected persons in Uganda reduces morbidity and mortality among HIV-uninfected family members.
    Mermin J; Lule J; Ekwaru JP; Downing R; Hughes P; Bunnell R; Malamba S; Ransom R; Kaharuza F; Coutinho A; Kigozi A; Quick R
    AIDS; 2005 Jul; 19(10):1035-42. PubMed ID: 15958834
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Feasibility and effectiveness of cotrimoxazole prophylaxis for HIV-1-infected adults attending an HIV/AIDS clinic in Uganda.
    Watera C; Todd J; Muwonge R; Whitworth J; Nakiyingi-Miiro J; Brink A; Miiro G; Antvelink L; Kamali A; French N; Mermin J
    J Acquir Immune Defic Syndr; 2006 Jul; 42(3):373-8. PubMed ID: 16810124
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Opportunities for improving the efficiency of paediatric HIV treatment programmes.
    Revill PA; Walker S; Mabugu T; Nathoo KJ; Mugyenyi P; Kekitinwa A; Munderi P; Bwakura-Dangarembizi M; Musiime V; Bakeera-Kitaka S; Nahirya-Ntege P; Walker AS; Sculpher MJ; Gibb DM
    AIDS; 2015 Jan; 29(2):201-10. PubMed ID: 25396263
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HIV-infected ugandan adults taking antiretroviral therapy with CD4 counts >200 cells/μL who discontinue cotrimoxazole prophylaxis have increased risk of malaria and diarrhea.
    Campbell JD; Moore D; Degerman R; Kaharuza F; Were W; Muramuzi E; Odongo G; Wetaka M; Mermin J; Tappero JW
    Clin Infect Dis; 2012 Apr; 54(8):1204-11. PubMed ID: 22423133
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Anti-inflammatory Effects of Cotrimoxazole Prophylaxis for People Living With Human Immunodeficiency Virus in Sub-Saharan Africa.
    Bourke CD; Prendergast AJ
    J Infect Dis; 2020 Jul; 222(3):347-350. PubMed ID: 31714953
    [No Abstract]   [Full Text] [Related]  

  • 28. Longitudinal effect of CD4 by cotrimoxazole use on malaria incidence among HIV-infected Ugandan adults on antiretroviral therapy: a randomized controlled study.
    Kasirye R; Grosskurth H; Munderi P; Levin J; Anywaine Z; Nunn A; Kamali A; Baisley K
    Malar J; 2016 Jul; 15():361. PubMed ID: 27417903
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of cotrimoxazole on mortality in HIV-infected adults on antiretroviral therapy: a systematic review and meta-analysis.
    Suthar AB; Granich R; Mermin J; Van Rie A
    Bull World Health Organ; 2012 Feb; 90(2):128C-138C. PubMed ID: 22423164
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early Height and Weight Changes in Children Using Cotrimoxazole Prophylaxis With Antiretroviral Therapy.
    Boettiger DC; Muktiarti D; Kurniati N; Truong KH; Saghayam S; Ly PS; Hansudewechakul R; Van Nguyen L; Do VC; Sudjaritruk T; Lumbiganon P; Chokephaibulkit K; Bunupuradah T; Nik Yusoff NK; Wati DK; Mohd Razali KA; Fong MS; Nallusamy RA; Sohn AH; Kariminia A;
    Clin Infect Dis; 2016 Nov; 63(9):1236-1244. PubMed ID: 27470239
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reduction in preterm delivery and neonatal mortality after the introduction of antenatal cotrimoxazole prophylaxis among HIV-infected women with low CD4 cell counts.
    Walter J; Mwiya M; Scott N; Kasonde P; Sinkala M; Kankasa C; Kauchali S; Aldrovandi GM; Thea DM; Kuhn L
    J Infect Dis; 2006 Dec; 194(11):1510-8. PubMed ID: 17083035
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increased monocyte and T-cell activation in treated HIV+ Ugandan children: associations with gut alteration and HIV factors.
    Dirajlal-Fargo S; Albar Z; Bowman E; Labbato D; Sattar A; Karungi C; Nazzinda R; Funderburg N; Kityo C; Musiime V; McComsey GA
    AIDS; 2020 Jun; 34(7):1009-1018. PubMed ID: 32073452
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cotrimoxazole prophylaxis and tuberculosis risk among people living with HIV.
    Hoffmann CJ; Chaisson RE; Martinson NA
    PLoS One; 2014; 9(1):e83750. PubMed ID: 24421903
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cotrimoxazole resistance in Streptococcus pneumoniae isolated from sputum of HIV-positive patients.
    Adeleye A; Uju L; Idika N; Sobande O
    West Indian Med J; 2008 Nov; 57(5):497-9. PubMed ID: 19565983
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alteration of the gut fecal microbiome in children living with HIV on antiretroviral therapy in Yaounde, Cameroon.
    Abange WB; Martin C; Nanfack AJ; Yatchou LG; Nusbacher N; Nguedia CA; Kamga HG; Fokam J; Kennedy SP; Ndjolo A; Lozupone C; Nkenfou CN
    Sci Rep; 2021 Apr; 11(1):7666. PubMed ID: 33828220
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The cost-effectiveness of cotrimoxazole prophylaxis in HIV-infected children in Zambia.
    Ryan M; Griffin S; Chitah B; Walker AS; Mulenga V; Kalolo D; Hawkins N; Merry C; Barry MG; Chintu C; Sculpher MJ; Gibb DM
    AIDS; 2008 Mar; 22(6):749-57. PubMed ID: 18356605
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cotrimoxazole prophylaxis for opportunistic infections in children with HIV infection.
    Grimwade K; Swingler GH
    Cochrane Database Syst Rev; 2006 Jan; 2006(1):CD003508. PubMed ID: 16437457
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reconstitution of intestinal CD4 and Th17 T cells in antiretroviral therapy suppressed HIV-infected subjects: implication for residual immune activation from the results of a clinical trial.
    d'Ettorre G; Baroncelli S; Micci L; Ceccarelli G; Andreotti M; Sharma P; Fanello G; Fiocca F; Cavallari EN; Giustini N; Mallano A; Galluzzo CM; Vella S; Mastroianni CM; Silvestri G; Paiardini M; Vullo V
    PLoS One; 2014; 9(10):e109791. PubMed ID: 25340778
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The independent effect of highly active antiretroviral therapy on severe opportunistic disease incidence and mortality in HIV-infected adults in Côte d'Ivoire.
    Losina E; Yazdanpanah Y; Deuffic-Burban S; Wang B; Wolf LL; Messou E; Gabillard D; Seyler C; Freedberg KA; Anglaret X
    Antivir Ther; 2007; 12(4):543-51. PubMed ID: 17668563
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Childhood malnutrition: toward an understanding of infections, inflammation, and antimicrobials.
    Jones KD; Thitiri J; Ngari M; Berkley JA
    Food Nutr Bull; 2014 Jun; 35(2 Suppl):S64-70. PubMed ID: 25069296
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.